Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Buy
55
ALPMY Quote, Financials, Valuation and Earnings
Last price:
$9.60
Seasonality move
:
1.21%
Day range:
$9.59 - $9.80
52-week range:
$8.37 - $13.14
Dividend yield:
5.23%
P/E ratio:
50.19x
P/S ratio:
1.36x
P/B ratio:
1.71x
Volume:
146.1K
Avg. volume:
187.9K
1-year change:
-7.66%
Market cap:
$17.3B
Revenue:
$12.6B
EPS (TTM):
$0.19
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Astellas Pharma has -- downside to fair value with a price target of -- per share.
ALPMY vs. S&P 500
-
Over the past 5 trading days, Astellas Pharma has overperformed the S&P 500 by 1.84% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Astellas Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Astellas Pharma has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Astellas Pharma reported revenues of $3.4B.
Earnings Growth
-
Astellas Pharma has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Astellas Pharma reported earnings per share of -$0.36.
Enterprise value:
21.4B
EV / Invested capital:
--
Price / LTM sales:
1.36x
EV / EBIT:
63.29x
EV / Revenue:
1.68x
PEG ratio (5yr expected):
--
EV / Free cash flow:
36.09x
Price / Operating cash flow:
28.00x
Enterprise value / EBITDA:
12.88x
Gross Profit (TTM):
$10.4B
Return On Assets:
1.49%
Net Income Margin (TTM):
2.72%
Return On Equity:
3.42%
Return On Invested Capital:
2.1%
Operating Margin:
-22.07%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $11.2B | $11B | $11.8B | $2.9B | $3.4B | |
| Gross Profit | $9B | $9B | $9.6B | $2.3B | $2.7B | |
| Operating Income | $1.2B | $69.4M | -$952.5M | $127.8M | -$748.7M | |
| EBITDA | $2.1B | $1.1B | $392.3M | $454.6M | -$412.8M | |
| Diluted EPS | $0.54 | -$0.01 | -$0.43 | $0.05 | -$0.36 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.9B | $7.6B | $7.9B | $7.9B | $8B | |
| Total Assets | $20.6B | $19.1B | $18.4B | $23.6B | $22.3B | |
| Current Liabilities | $5.4B | $5.6B | $5.4B | $8.5B | $7.1B | |
| Total Liabilities | $8B | $7.1B | $7.1B | $13B | $12.2B | |
| Total Equity | $12.6B | $12B | $11.3B | $10.5B | $10.1B | |
| Total Debt | -- | -- | $938.1M | $6.1B | $5.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2023-03-31 | 2024-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.3B | $2.4B | $1.2B | $922.3M | $514.6M | |
| Cash From Investing | -$556M | -$625.8M | -$5.9B | -$187.6M | -$283.1M | |
| Cash From Financing | -$1.9B | -$1.4B | $4.3B | -$802.4M | $306M | |
| Free Cash Flow | $1.6B | $1.8B | $623.5M | $695.2M | $366.7M | |
ALPMY
Sector
Market Cap
$17.3B
$34.4M
Price % of 52-Week High
73.36%
48.88%
Dividend Yield
5.23%
0%
Shareholder Yield
6.16%
-1.01%
1-Year Price Total Return
-7.66%
-37.36%
Beta (5-Year)
0.221
0.614
Dividend yield:
5.23%
Annualized payout:
$0.50
Payout ratio:
--
Growth streak:
10 years
Technicals
8-day SMA
Buy
Level
$9.52
200-day SMA
Sell
Level
$10.06
Bollinger Bands (100)
Buy
Level
9.33 - 9.93
Chaikin Money Flow
Buy
Level
7.5M
20-day SMA
Buy
Level
$9.52
Relative Strength Index (RSI14)
Buy
Level
52.18
ADX Line
Buy
Level
13.72
Williams %R
Neutral
Level
-54.8387
50-day SMA
Buy
Level
$9.60
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Sell
Level
-748.4K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.821)
Sell
CA Score
(Annual)
Level (-0.417)
Buy
Beneish M-Score
(Annual)
Level (-2.5338)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-0.9121)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
Stock Forecast FAQ
In the current month, ALPMY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ALPMY average analyst price target in the past 3 months is --.
-
Where Will Astellas Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Astellas Pharma share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Astellas Pharma?
Analysts are divided on their view about Astellas Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Astellas Pharma is a Sell and believe this share price will rise from its current level to --.
-
What Is Astellas Pharma's Price Target?
The price target for Astellas Pharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ALPMY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Astellas Pharma is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ALPMY?
You can purchase shares of Astellas Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Astellas Pharma shares.
-
What Is The Astellas Pharma Share Price Today?
Astellas Pharma was last trading at $9.60 per share. This represents the most recent stock quote for Astellas Pharma. Yesterday, Astellas Pharma closed at $9.64 per share.
-
How To Buy Astellas Pharma Stock Online?
In order to purchase Astellas Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
How High Can SharkNinja Stock Go?
If you know popular consumer appliance brands Shark and Ninja,…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 11.99% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.51% over the past day.
Sell
42
VLCN alert for Jul 17
Volcon [VLCN] is up 187.94% over the past day.
